Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): primary analysis results of a multicentre, open-label, randomised phase 2–3 trialDavid Cunningham, Ruth E. Langley, Sally Stenning et al.|The Lancet Oncology|2017Cited by 286
Neoadjuvant cisplatin and fluorouracil versus epirubicin, cisplatin, and capecitabine followed by resection in patients with oesophageal adenocarcinoma (UK MRC OE05): an open-label, randomised phase 3 trialDerek Alderson, Ruth E. Langley, David Cunningham et al.|The Lancet Oncology|2017Cited by 223
ADD-ASPIRIN: A phase III, double-blind, placebo controlled, randomised trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common non-metastatic solid tumoursC. Coyle, Ruth E. Langley, Fay Cafferty et al.|Contemporary Clinical Trials|2016Cited by 162
Development and validation of deep learning classifiers to detect Epstein-Barr virus and microsatellite instability status in gastric cancer: a retrospective multicentre cohort studyHannah Sophie Muti, Jakob Nikolas Kather, Takaki Yoshikawa et al.|The Lancet Digital Health|2021Cited by 120
Neoadjuvant chemotherapy for resectable oesophageal and junctional adenocarcinoma: Results from the UK Medical Research Council randomised OEO5 trial (ISRCTN 01852072).Derek Alderson, David Cunningham, Ruth E. Langley et al.|Journal of Clinical Oncology|2015Cited by 80